These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7494560)

  • 1. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
    Linz W; Wiemer G; Schaper J; Zimmermann R; Nagasawa K; Gohlke P; Unger T; Schölkens BA
    Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):89-97. PubMed ID: 7494560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
    Linz W; Wiemer G; Schölkens BA
    Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.
    Rhaleb NE; Yang XP; Scicli AG; Carretero OA
    Hypertension; 1994 Jun; 23(6 Pt 2):865-8. PubMed ID: 7515854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.
    Farhy RD; Carretero OA; Ho KL; Scicli AG
    Circ Res; 1993 Jun; 72(6):1202-10. PubMed ID: 7684331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of bradykinin to the cardiovascular effects of ramipril.
    Linz W; Wiemer G; Schölkens BA
    J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S1-8. PubMed ID: 7514234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
    Nolly H; Miatello R; Damiani MT; Abate CD
    Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
    Gohlke P; Linz W; Schölkens B; Van Even P; Martorana P; Unger T
    Br J Clin Pract Suppl; 1996 Jul; 84():1-10. PubMed ID: 8994995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
    Zhu YC; Zhu YZ; Gohlke P; Stauss HM; Unger T
    Am J Cardiol; 1997 Aug; 80(3A):110A-117A. PubMed ID: 9293963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.
    Gohlke P; Kuwer I; Schnell A; Amann K; Mall G; Unger T
    Hypertension; 1997 Jan; 29(1 Pt 2):478-82. PubMed ID: 9039145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
    Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
    Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
    Rumble JR; Komers R; Cooper ME
    J Hypertens; 1996 May; 14(5):601-7. PubMed ID: 8762203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
    Linz W; Gohlke P; Unger T; Schölkens BA
    Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():31-4. PubMed ID: 7646309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.
    Gohlke P; Linz W; Schölkens BA; Kuwer I; Bartenbach S; Schnell A; Unger T
    Hypertension; 1994 Apr; 23(4):411-8. PubMed ID: 8144208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.
    Linz W; Schölkens BA
    Br J Pharmacol; 1992 Apr; 105(4):771-2. PubMed ID: 1324047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.
    Linz W; Schaper J; Wiemer G; Albus U; Schölkens BA
    Br J Pharmacol; 1992 Dec; 107(4):970-5. PubMed ID: 1334756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.
    Ogawa T; Linz W; Stevenson M; Bruneau BG; Kuroski de Bold ML; Chen JH; Eid H; Schölkens BA; de Bold AJ
    Circulation; 1996 Jun; 93(11):2059-67. PubMed ID: 8640983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.
    Rouleau JL; Kapuku G; Pelletier S; Gosselin H; Adam A; Gagnon C; Lambert C; Meloche S
    Circulation; 2001 Aug; 104(8):939-44. PubMed ID: 11514383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].
    Grima M; Anjuère J; Ingert C; Coquard C; Steger J; Barthelmebs M; Imbs JL
    Arch Mal Coeur Vaiss; 2001 Aug; 94(8):805-12. PubMed ID: 11575208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
    Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
    Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.